A agilent.com: Price-to-Projected Revenue Ratio

Corporate emblem and logo of Agilent Technologies, Inc. (A)

Agilent Technologies is optimizing costs by sourcing basic electronics from external partners while maintaining its own R&D. The forward price-to-sales ratio clearly demonstrates the business valuation trend, with the current figure standing at 5.00. Agilent Technologies maintains its status as the gold standard in analytical chemistry. An impeccable image and the trust of the global scientific community make the brand a benchmark for diagnostic equipment precision.

A (Agilent Technologies, Inc.) Price to Expected Revenue Ratio history from 07/04/2022 to 11/13/2026

Analytical breakdowns for Agilent Corp (A)

- current price and projected stock value:
- company stock capitalization data:
Initial company analysis:Agilent A
Manufactured products of Agilent Corp

The forward P/S ratio assesses the market value of a business relative to its projected revenue, identifying whether an asset is overbought or undervalued. By analyzing the projected P/S value, an investor determines the extent to which current capitalization is justified by future cash flows. For Agilent Technologies (A), this multiple reflects market confidence in the scaling of high-tech robotic assembly and the implementation of AI diagnostics, which are expected to ensure stable sales growth.

Competitors of Agilent Technologies (A)

Forward P/S Multiple DGX (Quest Diagnostics Incorporated)|Illumina Inc (ILMN) - Market Cap to Future Revenue Ratio|EXAS - Price-to-Projected Revenue Ratio|RVTY (Revvity Corp) - Market Cap to Projected Revenue|BIO (Bio-Rad Laboratories) - Forward Price-to-Revenue Multiple|NNNN: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple SHC|QDEL: Forward Price to Sales|Forward Price-to-Revenue Multiple OPK (OPKO Corp)|Price to Expected Revenue Ratio CDNA|Forward P/S Multiple MRVI (Maravai LifeSciences)|fulgentgenetics.com (FLGT) - Market Cap to Future Revenue Ratio|Standard BioTools - Forward P/S Multiple|Cytek Biosciences Inc (CTKB) - Forward Price-to-Revenue Multiple|OSUR: Forward P/S Multiple|Exagen - Forward Price to Sales|Price-to-Projected Revenue Ratio MDxHealth SA|Market Cap to Projected Revenue LUCD (luciddx.com)|Price-to-Projected Revenue Ratio Prenetics Global (PRE)|IMDX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Trinity Biotech TRIB|ProPhase Labs Corp - Price-to-Projected Revenue Ratio|AIMD - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio codiagnostics.com|HSCS: Forward P/S Multiple|Projected Price to Revenue Biomerica Inc. BMRA|CDIO (Cardio Diagnostics Holdings Inc.) - Forward P/S Multiple|Onconetix Corporation (ONCO) - Market Cap to Expected Sales Ratio|Forward P/S Multiple VRAX|BJDX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Aspira Women's Health Inc. AWH|Market Cap to Expected Sales Ratio Accelerate Diagnostics Inc. (AXDX)|centogene.com - Forward P/S Multiple|ENZ - Forward P/S Multiple|fresh2.co (FRES) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Genetic Technologies Limited|ME (23andMe) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Psychemedics Corp. PMD